PLASMOLOGY4
OperatingPlasmology4, Inc.
Healthcare · Technology · Scottsdale, AZ · Founded 2010
Revolutionary technology for healthcare
Financials
FY2022–FY2025 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round.
Share price over rounds
Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.
Cap table
Principal holders% as the filing states it, May 5, 2026
- DJJ Trust15,954,372 Common Stock13.7%of company
Sold to the crowd
- Reg CF · Oct 2024622,881 shares at $1.17$728.8K· 215 investors
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
14 people
Seasoned executive with 30+ years of experience in the medical tech/device industry. Extensive experience in the spine surgery, orthopedic surgery and wound care market segments. Named inventor of 20+ patents and patent applications. Robert will be providing Form C sign-off as the Company's Principal Accounting Officer.
Experienced IT system and software architect, with expertise in business process design, operations, accounting, and ERP systems.
Experienced biomedical researcher with expertise in non-thermal plasma research, startup product development and regulatory strategies. Recipient of a prestigious IMPRS fellowship from the Max Planck Institute in Germany.
15+ years of experience designing medical devices, with several devices currently on market. 8 issued patents related to medical devices.
A skilled laboratory manager specializing in microbiology, she has dedicated her career to advancing the Plaz4 technology platform, with a strong focus on non-thermal plasma research.
Founder and Chairman of Board of Directors of The CORE Institute and Healthcare Outcomes Performance Company (HOPCo). Board certified by the American Academy of Orthopedic Surgeons. International speaker and authority on complex adult joint reconstruction, orthopedic oncology, and orthopedic soft tissue infections.
Show 5 more peopleShow fewer
Founder, President and Chairman of the Board of the Florida Orthopedic Institute, Tampa, FL. Has authored over 100 articles and abstracts on orthopedic trauma, published several textbooks on orthopedic trauma, and is presently the Editor-in-Chief of the Journal of Orthopedic Trauma, the leading international journal in the field.
Professor of Surgery and Orthopedic Surgery at the Mayo Clinic in Rochester, MN. Chair of the Division of Plastic Surgery and Reconstructive Surgery and the surgical director of hand transplantation at Mayo Clinic's Essam and Dalal Obaid Center for Reconstructive Transplant Surgery.
Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 2 of 2 annual reports (FY2024–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 20 filings on EDGAR- Form C-ARMay 5, 20260001488790-26-000005EDGAR
- Form C-ARApr 28, 20250001665160-25-000780EDGAR
- Form C-UApr 1, 20250001665160-25-000506EDGAR
- Form C/AFeb 14, 20250001665160-25-000254EDGAR
- Form C/AJan 13, 20250001665160-25-000047EDGAR
- Form COct 21, 20240001665160-24-001425EDGAR
- Form DDec 15, 20160001596771-16-000172EDGAR
- Form DApr 5, 20160001488790-16-000006EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.